- STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADAYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.STAT · 1mo ago↗ source
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugBoehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.STAT · 1mo ago↗ source
- STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet endingYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.STAT · 1mo ago